T1	Participants 102 132	familial adenomatous polyposis
T2	Participants 237 288	patients with familial adenomatous polyposis (FAP).
T3	Participants 951 1022	21 and 20 FAP patients, who received sulindac and placebo, respectively
T4	Participants 1044 1055	41 patients
